Abstract:Background: Although conventional pain relief therapeutics have centered around mu-opioid agonists, these drugs are limited by adverse side effects, including respiratory depression and addiction potential. The ongoing opioid epidemic has galvanized research into novel analgesic therapies with more favorable profiles. New pharmacologic agents have been developed to target neuronal pathways involved in pain sensation. Certain receptors have been recognized to mediate nociceptive transmission, central sensitization, and the development of chronic pain states. Objectives: We conducted a literature review to identify potential targets for novel analgesic therapies. Study design: This study is a narrative review of potential analgesic targets. We characterize their antinociceptive mechanisms of action and evaluate their therapeutic potential. Methods: A systemized search of available literature on novel analgesics was performed. A search was performed through the PubMed database to identify articles with key words of "novel analgesics," "novel non-opioid analgesics," "novel pain targets," and "non-opioid analgesics." Potential drug classes were identified and researched through corresponding keywords, with an emphasis on publications from 2018 to 2020. Older articles were included if frequently referenced by current literature. Results: Potential novel analgesic targets include Nav1.7, Nav1.8, CaV2.2, and transient receptor potential vanilloid-1 (TRPV1) cation channel receptors in the peripheral nervous system. Other approaches disrupt the synthesis of pronociceptive signaling molecules such as nitric oxide, prostaglandin E2, and interleukin-6 (IL-6). Within central pain pathways, modification of kappa-opioid, delta-opioid, N-methyl-D-aspartate, and cannabinoid receptors have been investigated in chronic pain and hyperalgesia models. Recent advances in molecular technology have also presented opportunities to modify protein expression or the cellular genome altogether. Limitations: Several analgesic targets have only demonstrated efficacy in preclinical trials. There are limited data evaluating the long-term safety profiles of therapies further on in development. Conclusions: We provide an overview of potential analgesic therapies in various stages of development, which may become clinically relevant in the near future. Some drugs such as TRPV1 agonists, anti-IL-6, and anti-nerve growth factor antibodies have demonstrated analgesic effect in specific clinical pain states.

Natural pain killers from marine sources: a new frontier in neurosurgical pain management

Marine bioactives: a new frontier in neurosurgical therapeutics

Drug development from marine natural products

Analgesic Peptides: From Natural Diversity to Rational Design

Conotoxins: emerging analgesics for neck and spinal surgery pain management

Novel Local Anesthetics in Clinical Practice: Pharmacologic Considerations and Potential Roles for the Future

Marine Natural Products with Anti-Inflammation Effects

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Marine natural products as source of new drugs: a patent review (2015–2018)

Marine Natural Products in Clinical Use

Marine Microorganism Molecules as Potential Anti-Inflammatory Therapeutics

Targeting Neuropathic Pain: Pathobiology, Current Treatment and Peptidomimetics as a New Therapeutic Opportunity

From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design

Trends on Nanomedicines as Novel therapeutics Approach in Targeting Nociceptors for Relieving Pain

Marine Natural Products — a Vital Source of Novel Biotherapeutics

Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain

Novel marine natural products as effective TRPV1 channel blockers

Recent Advances in Anti-Inflammatory Compounds from Marine Microorganisms

Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

Nanomedicine and voltage-gated sodium channel blockers in pain management: a game changer or a lost cause?